Arefa MD's Morning Report: Diabetes Intensification, CV Risk in Women, Thyroid Cancer
Dr Arefa Cassoobhoy provides a quick rundown of this week ' s news on intensification of therapy for type 2 diabetes, cardiovascular risk in premenopausal women, and overdiagnosis of thyroid cancer. (Source: Medscape Medscape Podcast)
Source: Medscape Medscape Podcast - August 26, 2016 Category: Journals (General) Authors: Medscape Source Type: podcasts
Individualized Diabetes Care: Not a 'Daunting Task'
What ' s the optimal drug combination for managing type 2 diabetes? It depends on the patient … (Source: Medscape Diabetes & Endocrinology Podcast)
Source: Medscape Diabetes & Endocrinology Podcast - July 22, 2016 Category: Endocrinology Authors: Medscape Source Type: podcasts
Individualized Diabetes Care: Not a 'Daunting Task'
What ' s the optimal drug combination for managing type 2 diabetes? It depends on the patient … (Source: Medscape Nurses Podcast)
Source: Medscape Nurses Podcast - July 22, 2016 Category: Nursing Authors: Medscape Source Type: podcasts
FDA Drug Safety Podcast: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
On June 14, 2016, FDA strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (brand names Invokana, Invokamet) and dapagliflozin (brand names Farxiga, Xigduo XR). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - June 21, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA announced that a safety review has found type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure
FDA announced that a safety review has found type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - April 27, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Association Between Sitagliptin Use and Heart Failure Hospitalization (JAMA Cardiology)
Interview with Darren McGuire, MD, author of Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus, and Benjamin Scirica, MD, author of The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - April 13, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
DPP4 Inhibitors for Diabetes and the Risk for Heart Failure (JAMA Cardiology)
Interview with Darren McGuire, MD, author of Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus, and Benjamin Scirica, MD, author of The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - April 13, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA Cardiology : DPP4 Inhibitors for Diabetes and the Risk for Heart Failure
Interview with Darren McGuire, MD, author of Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus, and Benjamin Scirica, MD, author of The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - April 13, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
FDA Drug Safety Podcast: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines
On December 16, 2015, the FDA announced it is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics. The REMS is no longer necessary to ensure that the benefits of rosiglitazone medicines outweigh their risks. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 30, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
On December 4, 2015, FDA announced a safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of ketoacidosis and of serious urinary tract infections (UTIs). Both conditions can result in hospitalization. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 30, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Treating Geriatric Polypharmacy by Deintensifying Unnecessary Diabetes Treatment
Polypharmacy is a rapidly worsening problem that hits elderly patients particularly hard. As patients grow older, they need more medications but at the same time become less capable of managing the complexity of drug treatments. In order to simplify treatment regimens for older patients, it is necessary to consider the evidence supporting treatment of various conditions and when the evidence is not particularly strong, reduce or eliminate medications accordingly. Diabetes management in the elderly is highlighted in this podcast with specific attention given to deintensifying diabetes treatment in the elderly.
Artic...
Source: JAMA Author Interviews - March 8, 2016 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Type 2 Diabetes Management: Choosing the Best Therapies
Two experts offer tips for sifting through the many drug options to help patients optimize management of their type 2 diabetes. (Source: Medscape Diabetes & Endocrinology Podcast)
Source: Medscape Diabetes & Endocrinology Podcast - October 9, 2015 Category: Endocrinology Authors: Medscape Source Type: podcasts
Sep 18 Cardiology News
The SPRINT hypertension trial announcement, ABIM concessions, frailty as a predictor of PCI outcomes, and high interval training as therapy in type 2 diabetes are discussed in this week's podcast. (Source: Medscape Cardiology Podcast)
Source: Medscape Cardiology Podcast - September 18, 2015 Category: Cardiology Authors: Medscape Source Type: podcasts
Guillermo E. Umpierrez, MD, CDE, FACP, FACE - Individualized Treatment Selection for Patients With Type 2 Diabetes: Considering the Role of the GLP-1 Receptor Agonists in the Context of Other Therapies
Individualized Treatment Selection for Patients With Type 2 Diabetes: Considering the Role of the GLP-1 Receptor Agonists in the Context of Other Therapies (Source: PeerView CME/CE Audio Podcast - Primary Care)
Source: PeerView CME/CE Audio Podcast - Primary Care - June 1, 2015 Category: Primary Care Authors: Answers in CME Tags: Science, Medicine Source Type: podcasts
Guillermo E. Umpierrez, MD, CDE, FACP, FACE - Assessing the Benefits and Limitations of the GLP-1 Receptor Agonists in the Management of Type 2 Diabetes
(Source: PeerView CME/CE Audio Podcast - Endocrinology)
Source: PeerView CME/CE Audio Podcast - Endocrinology - May 8, 2015 Category: Endocrinology Authors: Answers in CME Tags: Science, Medicine Source Type: podcasts
